CClinicalTrials.gg
Sign In
Not yet recruitingNCT07354035REVIVE-RCTUpdated Jan 21, 2026

The Coronary Sinus Balloon Pump in STEMI

An interventional study of The coronary sinus balloon pump and Percutaneous Coronary Intervention (PCI) in STEMI, sponsored by Shanghai MicroPort Rhythm MedTech Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Shanghai MicroPort Rhythm MedTech Co., Ltd. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is a prospective, multicenter, randomized controlled clinical trial designed to evaluate the safety and efficacy of the coronary sinus balloon pump (manufactured by Shanghai MicroPort Rotapace Medical Technology Co., Ltd.) as an adjunctive therapy during percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI). As a pivotal study, it aims to support the product registration application to the National Medical Products Administration (NMPA).

02

Conditions studied

  • STEMI
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

General Inclusion Criteria:

  1. Subjects aged ≥18 and ≤80 years, clinically diagnosed with ST-segment elevation myocardial infarction (STEMI).
  2. Left ventricular ejection fraction (LVEF) ≤50% and ≥35% as assessed by echocardiography or left ventriculography prior to PCI.
  3. Symptoms of myocardial infarction (e.g., persistent chest pain, with or without shortness of breath, nausea/vomiting, profuse sweating, dyspnea, syncope) consistent with the timing of myocardial ischemia, with symptom onset within 24 hours.

  4. Electrocardiographic evidence of acute anterior wall myocardial infarction, defined as ST-segment elevation ≥1 mm (0.1 mV) in at least two contiguous precordial leads on a 12-lead ECG. For leads V2 or V3, the following gender- and age-specific cutoffs apply:

    • 2 mm (0.2 mV) in men ≥45 years old.
    • 2.5 mm (0.25 mV) in men \<40 years old.
    • 1.5 mm (0.15 mV) in women.
  5. Subject is eligible for primary percutaneous coronary intervention (primary PCI).
  6. Subject is able to understand the purpose of the study, voluntarily agrees to participate by signing the informed consent form acknowledging the risks and benefits described therein, and is willing and able to comply with the required clinical follow-up procedures.

Angiographic Inclusion Criteria:

  1. The target lesion is located in the proximal or mid segment of the left anterior descending artery (LAD).
  2. TIMI flow grade of the target vessel is 0, 1, or 2 prior to PCI treatment.

Exclusion criteria

Exclusion Criteria:

  1. Presence of an implant or foreign body within the coronary sinus.
  2. The target lesion involves the left main coronary artery, or there is a ≥50% stenosis in the left main coronary artery.
  3. Known allergy or contraindication to drugs or materials required during PCI and the use of the investigational device (including, but not limited to, sirolimus, dual antiplatelet therapy drugs, polyamide, polyurethane, polytetrafluoroethylene, or stainless steel).
  4. Presence of pericardial effusion (moderate or greater), cardiac tamponade, hemodynamically significant left/right shunt, or severe valvular heart disease.
  5. Intracardiac thrombus detected by echocardiography within 30 days prior to enrollment.
  6. History of acute myocardial infarction, or documented history of hospitalization for Q-wave infarction.
  7. History of cerebral infarction, intracerebral hemorrhage, transient ischemic attack (TIA), or reversible ischemic neurologic deficit within the past 6 months, or presence of permanent neurological deficit.
  8. Known hemoglobin level below 90 g/L, platelet count below 80×10⁹/L, history of bleeding diathesis or coagulation disorder, or unwillingness to receive blood transfusion.
  9. Subjects requiring circulatory support or assisted ventilation.
  10. Subjects experiencing cardiac arrest or cardiopulmonary resuscitation (CPR) for more than 5 minutes preoperatively (baseline) or intraoperatively.
  11. Subjects unsuitable for femoral or jugular venous access.
  12. Known contraindications to cardiac magnetic resonance imaging (CMR), such as claustrophobia, presence of non-CMR compatible foreign bodies or implants, or allergy/intolerance to gadolinium-based contrast agents.
  13. Prior coronary artery bypass graft (CABG) surgery.
  14. Visible well-developed collateral circulation distal to the target lesion in the target vessel.
  15. Current participation in another clinical drug or device study where the primary endpoint has not been reached, or planned participation in another investigational drug or device clinical trial within 12 months after the baseline procedure.
  16. Known severe renal disease (estimated glomerular filtration rate (eGFR) \<30 mL/(min·1.73m²) as calculated by the MDRD formula*) or undergoing hemodialysis.
  17. History of treatment for malignancy within the past 12 months.
  18. Subjects with chronic obstructive pulmonary disease (COPD) who are on home oxygen therapy or receiving chronic steroid therapy.
  19. Impaired consciousness during PCI, cardiogenic shock (persistent systolic blood pressure ≤90 mmHg despite conservative treatment), or pulmonary edema (peripheral oxygen saturation \<90% with rales).
  20. Any vascular PCI treatment received within 1 week prior to enrollment.
  21. Fibrinolytic therapy received within 24 hours prior to enrollment.
  22. -target lesions in vessels other than the left anterior descending artery and its branches requiring treatment during this PCI or within one week thereafter.
  23. Known pregnancy or breastfeeding, or female subjects planning pregnancy within 1 year post-procedure and unable to complete follow-up as required.
  24. Subjects judged by the investigator to have poor compliance and unable to complete the study as required, or any other reason the investigator deems the subject unsuitable for enrollment.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
177 participants (estimated)

Study arms

  • Experimental
    The coronary sinus balloon pump +PCI

    Subjects in the experimental group will be treated with the coronary sinus balloon pump manufactured by Shanghai Microport Rotapace Co. Ltd.

    Device: The coronary sinus balloon pump · Procedure: Percutaneous Coronary Intervention (PCI)

  • Placebo comparator
    Standard PCI

    Procedure: Percutaneous Coronary Intervention (PCI)

Interventions

  • DeviceThe coronary sinus balloon pump

    The coronary sinus balloon pump comprises a coronary sinus balloon pump catheter system and a coronary sinus balloon pump therapeutic device. This product is indicated for the treatment of ST-segment elevation myocardial infarction (STEMI) with or without coronary microvascular dysfunction (CMD), by intermittently occluding coronary sinus blood flow during percutaneous coronary intervention (PCI) procedures to reduce myocardial infarction size.

  • ProcedurePercutaneous Coronary Intervention (PCI)

    Minimally invasive procedures used to open clogged coronary arteries

05

What researchers measure

Primary outcomes

  1. Myocardial infarct size

    Myocardial infarct size is measured by cardiac magnetic resonance (CMR) 5 days after the procedure, expressed as a percentage of left ventricular mass (%LV).

    Time frame: 5 days after the procedure

  2. Incidence of Major Adverse Events (MAE) (Experimental Group)

    Major Adverse Events (MAE) include: All-cause death Myocardial infarction Target vessel revascularization Hospitalization for heart failure New onset or worsening heart failure Coronary sinus dissection or perforation requiring intervention or surgical repair Thrombosis or thromboembolism Stroke Major bleeding (BARC Type 3\~5) Ventricular tachycardia or ventricular fibrillation requiring defibrillation or cardioversion

    Time frame: at 30 days post-procedure

Secondary outcomes

  1. Device Success Rate (Experimental Group)

    Successful delivery and deployment of the device to the coronary sinus and completion of the intended procedure

    Time frame: Immediately post-procedure

  2. Procedure Success Rate (Experimental Group)

    Achievement of PCI success based on device success, without the occurrence of any CSBP-related adverse events

    Time frame: Immediately post-procedure

  3. Coronary Sinus Pressure (Experimental Group)

    Time frame: Immediately post-procedure

  4. Change in ST-Segment Elevation

    Change in ST-Segment Elevation \[Comparison between post-PCI ECG and baseline\]

    Time frame: Immediately post-procedure

  5. Incidence of Device-Related Procedural Complications (Experimental Group)

    Procedural Complications are defined as: Access site complications (including access site bleeding of BARC Type 3-5, access site infection requiring oral or intravenous antibiotics, access site complication requiring surgical intervention), coronary sinus dissection or perforation requiring intervention or surgical repair, pericardial effusion or cardiac tamponade requiring intervention or surgical treatment, thrombosis or thromboembolism, and stroke. The relatedness of a procedural complication to the device must be adjudicated by the Clinical Events Committee (CEC).

    Time frame: Immediately post-procedure

  6. Death (cardiac, vascular, non-vascular)

    Rate of death (cardiac, vascular, non-vascular), as adjudicated by the Clinical Events Committee (CEC)

    Time frame: at 5 days, 30 days, 6 months, and 12 months post-procedure

  7. Rate of heart failure hospitalization

    Time frame: at 5 days, 30 days, 6 months, and 12 months post-procedure

  8. Incidence of new-onset or worsening heart failure

    Time frame: at 5 days, 30 days, 6 months, and 12 months post-procedure

  9. Incidence of myocardial infarction

    Time frame: at 5 days, 30 days, 6 months, and 12 months post-procedure

  10. Incidence of revascularization (target lesion, target vessel, any coronary)

    Time frame: at 5 days, 30 days, 6 months, and 12 months post-procedure

  11. Incidence of stent thrombosis

    Time frame: at 5 days, 30 days, 6 months, and 12 months post-procedure

  12. Incidence of major bleeding events

    Time frame: at 5 days, 30 days, 6 months, and 12 months post-procedure

  13. Incidence of stroke

    Time frame: at 5 days, 30 days, 6 months, and 12 months post-procedure

  14. Severity of angina

    Angina severity (classified according to the Canadian Cardiovascular Society Classification of Angina Pectoris) is assessed by the level of physical activity that triggers the chest pain. And the lower the level that triggers the chest pain, the more serious angina.

    Time frame: at 5 days, 30 days, 6 months, and 12 months post-procedure

  15. Ventricular tachycardia or ventricular fibrillation requiring defibrillation or cardioversion

    Ventricular tachycardia or ventricular fibrillation requiring defibrillation or cardioversion as adjudicated by the CEC

    Time frame: at 5 days, 30 days, 6 months, and 12 months post-procedure

  16. EQ-5D quality of life score

    Changes in quality of life measured by EQ-5D (assessed by the following five dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression) (scale of 0-100: higher score better)

    Time frame: at 5 days, 30 days, 6 months, and 12 months post-procedure

  17. Incidence of adverse events and serious adverse events

    Time frame: at 5 days, 30 days, 6 months, and 12 months post-procedure

  18. Incidence of device deficiencies (Experimental Group only)

    Time frame: at 5 days, 30 days, 6 months, and 12 months post-procedure

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT07354035
Lead sponsor
Shanghai MicroPort Rhythm MedTech Co., Ltd.
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Feb 12, 2026 (estimated)
Primary completion
May 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Jan 21, 2026

Study contacts

Tingting Wu
Contact
TingTing.Wu2@microport.com
0086-021-38954600
Kefei Do
Contact

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

ST Elevation Myocardial Infarction→

Other studies from this sponsor

Shanghai MicroPort Rhythm MedTech Co., Ltd.

Start the discussion